logo-loader
viewbit bio

Bit bio hopes to scale gene engineering platform following rebrand

Snapshot

  • bit bio is pioneering the production of cells for research without animals
  • The goal is to develop a scalable technology platform capable of producing consistent batches of every human cell type
  • Recently bit bio agreed a distribution agreement with AIM-listed Abcam
bit bio -

What bit bio does

A spin-out from the University of Cambridge, bit bio develops proprietary technologies for the efficient and consistent reprogramming of human cells used in research, drug discovery, and cell therapy.

The company, formed in 2016 as Elpis Biomed, has built a gene engineering approach known as opti-ox (optimised inducible over-expression), which enables precise reprogramming of entire cultures of stem cells into any desired cell type.

Chief executive Mark Kotter says that cell therapy has potential in the treatment of cancer, but that research is being slowed by the limited availability of human cells to test on.

bit bio is hoping to build a scalable platform technology capable of producing any human cell type in order to meet the growing research need for access to human cells.

Developing the future

Last year, the company unveiled a new executive team, following its rebranding from Elpis Biomed.

The biotech is now headed by chief executive Mark Kotter, a stem cell biologist and neurosurgeon at the University of Cambridge, while Florian Schuster, the former finance boss of Tessa Therapeutics, is taking up the positions of chief financial and chief operations officer.

The firm’s chief business officer, meanwhile, is Paul Morrill, the co-founder of gene editing firm Horizon Discovery Group PLC (LON:HZD), with immune-oncology clinician Ramy Ibrahim and stem cell reprogramming specialist Marius Wernig serving as scientific advisors.

How it's doing

In February, bit bio signed an agreement with AIM-listed reagent distributor Abcam to make its iPSC derived functional human cells available to the global life science community.

The first product available will be brain cells for the neuroscience community.

Video

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of bit bio named herein, including the promotion by the Company of bit bio in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Bit bio developing a technology platform 'capable of...

Bit bio's Mark Kotter speaks to Proactive London's Andrew Scott following the name change from Elpis Biomed. The business has recently hired a number of industry heavy-hitters to its leadership team as it works towards its goal of developing a scalable platform technology capable of...

on 6/11/19

2 min read